Clinical Trials Browser

Phase 1/2 × Leukemia × Dasatinib × Clear all

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01498445 2020-10-22

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

Phase 1/2 Terminated

32 enrolled 16 charts

MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00829647 2019-04-11

A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia

Phase 1/2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01218477 2016-06-17

Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)

Phase 1/2 Completed

33 enrolled 18 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Chronic-Phase

Clinical Trials

HEM-iSMART B

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia

Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)